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Background.Magneticresonanceimagingisconsideredasimagingmodalityofchoiceindiagnosisofdesmoidtumors,thougheven
thistechniquecanlacktheabilitytodistinguishaggressiveﬁbromatosisfromotherbenignormalignantsofttissuetumors.Theaim
of this study was to investigate if desmoid tumors would show an adequate tracer uptake in somatostatin receptor scintigraphy and
moreover to correlate these results with immunohistochemical staining. Patients and Methods. Thirteen patients with desmoid
tumors were examined with somatostatin receptor scintigraphy. Additionally, seven of these patients have been tested for the
immunohistochemical expression of somatostatin receptor subtype 2A. The results of somatostatin receptor scintigraphy and the
results of immunohistochemical staining (somatostatin receptor subtype 2A) were evaluated and correlated. Results.S o m a t o s t a t i n
receptor scintigraphy revealed that eight of 13 aﬀected patients (62%) showed an enhanced tracer uptake. On the other hand,
the correlation between the results of somatostatin receptor scintigraphy and immunohistochemical investigations was poor (two
out of seven cases). Conclusion. The current study demonstrated that desmoid tumors frequently express somatostatin receptor
subtype 2, while immunohistochemical investigations did not correlate with these ﬁndings. This may likely be due to lack of
standardization of this technique and also due to heterogeneous receptor distribution within the tumors.
1.Introduction
Fibromatoses/desmoid tumors are ﬁbroblastic proliferations
with an intermediate dignity between benign ﬁbroblastic
tumors and ﬁbrosarcoma [1]. They are characterized by an
inﬁltrative growth pattern, high rate of local recurrence, and
the inability to metastasize [1–3]. Referring to Weiss and
Goldblum [3] there are two main groups of ﬁbromatoses-
superﬁcial (fascial) and deep (musculoaponeurotic) ﬁbro-
matosis. Furthermore, these tumors are divided into several
subcategories according to their anatomic location (abdom-
inal, extra-abdominal, intra-abdominal). Wide or radical
resection with negative microscopic surgical margins is
treatment of choice and a signiﬁcant prognostic factor in
p r i m a r yc a s ea sw e l la si nr e c u r r e n c ec a s e s( P<0.001) [4].
MRI represents the gold-standard imaging modality for
thepurposeofplanningmanagement,especiallysurgery,and
performing surveillance of desmoid patients in order to de-
tectdiseaseprogressionandpostoperativerecurrence[5–11].
Peptide receptor imaging (PRI) enables visualization of
receptor expressing tissues noninvasively [12, 13]. Further-
more, peptides labeled with β-radiation emitters can be used
to eradicate receptor expressing tissues (peptide receptor
radionuclide therapy PRRT) [13].
However, the best examples of targets for radiopeptide-
basedimagingaresomatostatinreceptors(SSTRs),sincethey
are frequently expressed in neuroendocrine tumors as well
as in a wide variety of other malignancies, even soft tissue
tumors [13, 14].2 ISRN Oncology
Table 1: Patient demographics, summarizing age, sex, type, and location of desmoid tumour, results of SRS (SRS was performed once
(SRS 1) and occasionally a second time (SRS 2)) and immunohistochemistry and followup in months. Tracer uptake was described as +
(enhanced) and − (nonpathological). SSTR 2A staining was described as 0 (absent), 1 (moderate), and 2 (distinct).
No. Sex and age Type, location and side Diagnosis SRS 1 SRS 2 SSTR 2A Followup
1 M, 44 Extra-abdominal ﬁbromatosis, upper arm, right 1st relapse In111− In111− 14 7
2 F, 52 Extra-abdominal ﬁbromatosis, thigh, right Primary tumor In111+I n 111+n . a . 6 1
3 F, 35 Abdominal ﬁbromatosis, abdomen, left Primary tumor In111− n.a. n.a. 19
4 F, 29 Extra-abdominal ﬁbromatosis, shoulder, right 1st relapse In111+ n.a. 0 134
5 M ,1 8 E x t r a - a b d o m i n a lﬁ b r o m a t o s i s ,l o w e rl i m b ,r i g h t 2 n dr e l a p s e I n 111+ n.a. n.a. 153
6 F, 20 Extra-abdominal ﬁbromatosis, upper limb, left Primary tumor In111+n . a . 0 / 0 9 3
7 F, 48 Abdominal ﬁbromatosis, abdomen, right Primary tumor In111− n.a. n.a. 6
8 M, 36 Extra-abdominal ﬁbromatosis, thigh, left 1st relapse In111+n . a . 0 7 1
9 M, 33 Extra-abdominal ﬁbromatosis, metacarpus, right 2nd relapse In111− n.a. n.a. 14
10 F, 27 Extra-abdominal ﬁbromatosis, planta pedis, right 2nd relapse In111+n . a . 1 5 4
11 M, 50 Extra-abdominal ﬁbromatosis, elbow, right 1st relapse Tc99m− n.a. 0/1 27
12 M, 52 Extra-abdominal ﬁbromatosis, shoulder, right Residual tumor Tc99m+T c 99m+1 1 5
13 F, 52 Extra-abdominal ﬁbromatosis, thoracic, right 1st relapse Tc99m+ n.a. n.a. 13
Studiesonsomatostatinreceptorscintigraphy(SRS)have
started in 1988 and have initially concerned with the use
of 123I-Tyr3-octreotide, which has already been abandoned
for practical reasons and cost concerns [15]. In 1994,
imaging with the radiopharmaceutical 111In-pentetreotide
(commercially available as OctreoScan) was approved for
patients with neuroendocrine tumors (NETs) [13]. Positive
scans reﬂect the presence of an increased density of SSTRs, in
particular SSTR 2 and SSTR 5 [16]. Nevertheless, the density
of SSTRs varies among diﬀerent tumors and therefore, the
sensitivity of 111In-pentetreotide also varies.
Therefore, new somatostatin analogues with similar
binding proﬁle and imaging quality but labeled with 99mTc
have frequently been studied and are growing in importance
[12,13,17],duetothecosteﬀectivenessandwideavailability
of this radioisotope [13, 18]. This somatostatin analogue
shows high aﬃnity to SSTR 2 and lowest to SSTR 5 [19].
Studies of various authors revealed several advantages of
99mTc-TOC compared to 111In-OCT, hence 99mTc-TOC
is considered as a promising radiopharmaceutical to replace
111In-OCT in diagnostic nuclear medicine [18, 20].
Althoughadvancedimagingmodalitiescanprovideclues
to the correct diagnosis of aggressive ﬁbromatosis, histo-
logical examination of tumour tissue remains the golden
diagnostic standard [5, 7, 9, 21].
Based on the report of de Pas et al. [22], the aim of
this retrospective study was to investigate the percentage of
desmoid tumors that express SSTR 2 and show adequate
tracer uptake in SRS. The hypotheses were that there is a low
percentage of SSTR 2 positive desmoid tumors and that only
few cases show adequate uptake in SRS.
2.MaterialsandMethods
Thirteen patients who have been treated for desmoid tumors
which have been histologically veriﬁed and who have been
examined with SRS since 1999 were included in the current
(Table 1). Gender distribution was balanced with six males
andsevenfemales.Meanageatdiagnosiswas38years(range,
18 to 52) and the average followup was 54 months (range,
6 to 153). Ten patients presented local recurrence and three
patients had their second relapse.
Most tumors occurred in typical anatomical regions.
Although deep ﬁbromatoses are rare on hands and feet, one
patient developed a metacarpal tumour. Another patient,
who initially presented with a proliferation of the lower leg,
developedaplantarrecurrence.Theextra-abdominaltumors
were located at the following anatomical sites—trunk: n = 1;
upper and lower extremities: n = 10, whereas six occurred in
the upper extremity and four in the lower one.
All patients were analyzed either for uptake of 111In-
DTPA-octreotide or for uptake of 99mTc-EDDA/HYNIC-
TOC. Furthermore, scintigraphic ﬁndings were correlated
with corresponding MR images as well as with immunohis-
tochemical expression of SSTR 2A. Immunohistochemical
staining and data analysis were performed whenever tissue
material was available.
2.1. Somatostatin Receptor Scintigraphy (SRS). Somatostatin
receptor scintigraphy was performed either preoperatively or
at suspicion of disease relapse, by using established radio-
pharmaceuticals, namely, either 111In-DTPA-octreotide or
99mTc-EDDA/HYNIC-TOC (Figure 1(a)). The tracers were
prepared with commercially available kits using standard
techniques as described by the producers. 111In-DTPA-
octreotide was used as tracer until 2008. Planar and SPECT
investigations of the tumour regions were performed 4 or 5
and 24 hours after application of the radioactive tracer. Since
2009 SRS has been performed with 99mTc-EDDA/HYNIC-
TOC, due to cost eﬀectiveness and a simplifying one-day
protocol. The scintigraphic procedure includes 1 and 4
hours postinjection planar and SPECT images of the tumour
regions. Tracer uptake was described as enhanced (+) or
nonpathological (−).ISRN Oncology 3
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Figure 1: Positive correlation of 111In-DTPA-octreotide scintigraphy and somatostatin receptor 2A immunohistochemistry. (a) Results of
SRS showing enhanced tracer uptake at the side of the desmoid tumour at the bottom of the foot and (b) moderate immunohistochemical
staining for somatostatin receptor subtype 2A (magniﬁcation ×40).
2.2. Immunohistochemistry. After methodological setting by
testing the SSTR 2A antibody (code SS-800, Biotrend Chem-
ikalien, Cologne, Germany), all cases of desmoid tumors
with available pathological material were retrospectively
analyzed for immunohistochemical expression of SSTR 2A
(Figure 1(b)).
All specimens were ﬁxed in formalin, routinely processed
and paraﬃn embedded. Immunohistochemical studies were
performed using an established speciﬁc rabbit polyclonal
antibody against SSTR 2A receptors (code SS-800, Biotrend
Chemikalien), more precisely against its carboxyl-terminus
(amino acid sequence 355–369 (ETQRTLLNGDLQTSI)).
T h et i s s u es e c t i o n sw e r ep r o c e s s e du n d e rt h et e r m so f
manufacture guidelines or standard protocols. Appropriate
positive and negative controls were included: specimens of
neuroendocrine tumours (NETs) were stained as positive
control, while normal human soft tissue was used as neg-
ative control. The staining pattern was described as absent
(score 0: no immunoreactivity), moderate (score 1: focal to
multifocal immunoreactivity in <50% of cells), and distinct
(score 2: immunoreactivity in >50% of cells). All slides were
evaluated independently by light microscopy by two of the
authors, including a senior pathologist (B. Atzwanger).
3. Results
3.1. Somatostatin Receptor Scintigraphy. Ten patients were
examined with SRS at least once and three were investigated
twice. In all three cases, the ﬁndings of the ﬁrst scintigraphy
correlated with the ﬁndings of the second investigation
(Table 1). Altogether, ﬁve cases showed nonpathological
tracer uptake (38%), while eight cases (62%) revealed
increased tracer uptake at tumour site and were there-
fore considered as SSTR expressing tumors (Figure 1(a)).
3.2. Immunohistochemistry: SSTR 2A. Tissue samples from
seven patients were available and were exclusively specimens
from extra-abdominal locations. In total, nine specimens
were tested for the expression of SSTR 2A, seven tissue
samples were from one location of the tumour and in two
cases, specimens from two various locations of the tumour
were investigated. Staining was moderate in four cases and
absent in ﬁve cases (Figure 1(b)). Distinct staining was not
found in any of the samples. In two cases, two tissue samples
of two various locations of the tumour were tested. One of
these samples stained neither in the ﬁrst nor in the second
location. The other sample did not stain in the ﬁrst location,
but revealed moderate staining in the second location.
3.3. Correlation of SRS and Immunohistochemistry. The ﬁnd-
ings of SRS and immunohistochemistry correlated in only
twopatients.Inthesecasesthedesmoidsshowedanadequate
tracer uptake in SRS and their tumour samples revealed
positive staining by immunohistochemistry (Figures 1(a)
and 1(b)). Altogether, ﬁve cases showed inconsistent SRS
results as compared with immunohistochemistry. Three of
these had adequate tracer uptake in SRS, while the tissue
samples revealed absent staining. On the other hand, in
one patient the tumour showed non-pathological tracer
uptake in SRS, while the tissue specimen stained moderately.
Another patient showed non-pathological tracer uptake in
SRS and the tissue sample revealed absent staining of one
location and moderate staining of the other location. In
conclusion,apositivecorrelationbetweenSRSandimmuno-
histochemistry could be found in two patients (29%).
4. Discussion
In the present investigation, 62% of the examined prolifer-
ations showed an enhanced tracer uptake at the site of the
desmoid lesion in SRS, hence these tumors were regarded
as SSTR expressing proliferations. Desmoids of ﬁve cases
(38%) showed nonpathological scintigraphic ﬁndings and,
consequently, were considered as SSTR negative lesions.4 ISRN Oncology
Furthermore, three patients, who have been investigated
twice, revealed correlating ﬁndings of the ﬁrst and the
second scintigraphy which is in agreement with the generally
admitted fact that recurrences usually express the same
receptors as the primary tumors and, additionally, show the
same tracer uptake pattern.
Somatostatinreceptorsarefrequentlyexpressedinawide
variety of neoplastic proliferations with soft tissue tumors
anddesmoidsbeingnoexception[14].Althoughtheamount
of SSTRs as well as the expressed subtypes are varying from
tumour to tumour and within one tumour, SSTR 2 is the
most frequently expressed subtype in the vast majority of
SSTR positive tumors [23] and, moreover, its splice variant
SSTR 2A has been shown to be the actually expressed
isoform [24, 25]. This is of diagnostic importance for SRS,
since commercially available radiopharmaceuticals contain
thesomatostatinanalogueoctreotideorderivatesofthesame
and have distinct aﬃnity to SSTR 2 and only moderate
aﬃnity to subtypes 3 and 5.
In 2003 data was published leading to the assumption
that desmoid tumors may express SSTRs as well. Florio et al.
[14] reported on four samples of aggressive ﬁbromatosis and
analyzed them for the expression of SSTRs by using RT-PCR
(RNA isolation and reverse transcription-polymerase 44
chain reaction). They found that two samples where negative
for all SSTR subtypes, while one abdominal ﬁbromatosis
expressed SSTR 1–4 and one extra-abdominal ﬁbromatosis
locatedonalimbexpressedSSTR1andSSTR5[14].In2003,
de Pas et al. [22] examined six patients with fast growing
relapses of desmoid tumors using SRS and found that two of
themwereSSTRpositive.Subsequently,theywereapparently
successfully treated (partial response or disease stabilization)
with 90Y-DOTATOC.
Immunohistochemical evaluation of SSTR 2A in human
tumors is well established and has been shown to be a fast
and reliable method [24]. De Pas et al. [22]r e p o r t e do n
ten patients with aggressive ﬁbromatosis, among whom two
showed immunopositivity to a rabbit polyclonal antibody
SSTR 2A. K¨ orner et al. [26] found that one antibody,
namely the commercially available SSTR 2A antibody (code
SS-800, Biotrend Chemikalien, Cologne, Germany), which
has also been used in the current study, is suitable for
routine immunohistochemical assessment of the SSTR 2A
status of neoplastic tissues. The main disadvantage of
immunohistochemical investigations of SSTRs is the general
lack of standardization concerning interpretation of staining
patterns, which results in problematic reproducibility of this
method [27]. In this series, nine specimens have been tested
for the expression of SSTR 2A. In our study only four cases
revealed a moderate staining by immunohistochemistry
whereas ﬁve cases were completely negative.
Several studies have directly compared the results of SRS
with corresponding immunohistochemical SSTR 2A investi-
gations and none of these concerned desmoid tumors [23,
27, 28]. Nevertheless, reasons for discrepant ﬁndings among
these two techniques are presumably independent from the
examined tumour type. As with this study, two various
constellations of discrepant SRS and immunohistochemistry
ﬁndings can occur: discrepancies between enhanced tracer
uptake in SRS and absent immunohistochemical staining for
SSTR 2A or nonpathological tracer uptake in SRS and posi-
tive immunohistochemical staining. For both constellations
several explaining theoretical approaches exist.
First, the somatostatin analogues used for SRS binding,
apart from SSTR 2, also the subtypes SSTR 3 and 5 with
moderate aﬃnity. Although SSTR 2 is the most frequent ex-
pressed receptor subtype in most tumors, it is possible that
scintigraphy results are positive because of the other two
receptorsubtypespredominatingwithinthelesion.However,
since this survey investigated immunohistochemical expres-
sion of SSTR 2A only, no assertion can be stated, though
some authors [23, 27] found that the analysis of the other
two receptors did not increase the congruency of the two
techniques.
Second, nonpathological tracer uptake in SRS can be
based upon a poor SSTR density and may be another ex-
planation for inconsistent results, since Asnacios et al. [28]
reported that nonpathological scintigraphy combined with
positive immunohistochemical staining implicate an overall
lower amount of positive tumour cells as compared with
correlative positive results of both techniques. In the current
study, the amount of immunohistochemical stained cells
in positive histological sections was lower than 50% in all
samplesandregardlessofenhancedornon-pathologicalSRS.
Degradation of SSTRs in tissue specimens with time may
another reason for the inconsistent results between SRS and
immunohistochemistry [23].
Another important factor might be the used antibody
for immunohistochemical staining as well as the area of its
binding. In an earlier series, our study group found positive
staining for somatostatin in only six of 46 extra-abdominal,
two of 21 abdominal, and one of 13 intra-abdominal
ﬁbromatoses (overall 11%) using a polyclonal, cytoplasmatic
somatostatin antibody (code A0566, Dako, Vienna, Austria)
[29]. In the current series, a surface antibody for SSTR 2A
(codeSS-800,BiotrendChemikalien)wasusedbeingpositive
in four of nine cases (44%), indicating higher speciﬁcity.
Several authors [23, 27] agree that the frequently found
heterogeneous distribution of SSTR subtypes in neoplasms
may be the most plausible explanation for both, discrepant
positive and discrepant negative results in immunohisto-
chemistry as compared with SRS. In concordance with
this assumption, the tissue sample of one patient with
discrepant results had been obtained by biopsy, thus it is
not representative for the SSTR expression pattern of the
whole tumour. Moreover, except for two tissue samples, only
one histological section per specimen has been examined
for the expression of SSTR 2A, which again seems to
be unrepresentative for the whole tumour. The tumors’
frequently found heterogeneity is also emphasized by the
tissue sample of one case that has been investigated on two
various locations and showed opposed results.
Nevertheless, the appropriate reasons for the discrepant
results remain elusive. The greatest problem seems to be
the general lack of standardization of immunohistochemical
SSTR analysis and, therefore, the development of standard-
ized scoring systems is of prime importance. Furthermore,
immunohistochemistry fails to provide information on theISRN Oncology 5
whole tumour and one histological section per tissue sample
seems diagnostically inconclusive. Consequently, immuno-
histochemistryseemstoprovidethemoreconvincingresults,
the more histological sections of diﬀerent locations of
o n et u m o u rh a v eb e e ni n v e s t i g a t e d .H o w e v e r ,t h ev a l u eo f
immunohistochemical SSTR 2A examinations of desmoid
tumors remains unclear and further investigations are
needed.
5. Conclusion
The current study demonstrated that desmoid tumors fre-
quently express SSTR 2. Overall, eight out of 13 desmoids
(62%) showed an enhanced tracer uptake. On the other
hand, immunohistochemical investigations for SSTR 2A did
not correlate with ﬁndings of somatostatin receptor scintig-
raphy.Thismaylikelybeduetothelackofstandardizationof
this technique as well as the heterogeneous receptor distribu-
tion within the tumors. Nevertheless, further investigations
are needed to determine the value of somatostatin recep-
tor scintigraphy and immunohistochemistry for desmoid
tumors.
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